This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

Good Prognostic indicators:

  • early onset and typical involvement - flexural surfaces
  • 90% resolution by early teens
  • may be recurrence of the disorder in adulthood if there are circumstances where there is undue stress of the skin eg the hands of a hairdresser

Poor Prognostic indicators:

  • a more guarded prognosis should be given to those where the condition has a later onset and/or a atypical pattern of involvement (ie extensor surfaces).

Evidence from the British 1958 birth cohort study (1) reveals:

  • in the context of children with reported or examined eczema by the age of 7 years
    • the proportion of children who were clear in terms of examined eczema or reported eczema in the last year at ages 11 and 16 years was 65% and 74%, respectively (these 'apparent' or short-term clearance rates fell to 53% and 65%, respectively, after allowance for subsequent recurrences in adolescence and early adulthood)

However the Odense Adolescence Cohort Study (TOACS) showed that up to 50% of patients had persistent eczema in adulthood (2)

Reference:

  • (1) Br J Dermatol 1998 Nov;139(5):834-9 The natural history of childhood eczema: observations from the British 1958 birth cohort study. Williams HC, Strachan DP.
  • (2) Mortz CG et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy 2015;70(7):836–45

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.